GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases. Gene editing therapies are seen to have huge scope in treating a range of diseases but none are ...